To All New Investors:
Buyer Beware.

This is why you always prepare for the worst, especially with a crooked company.
I'm not at all surprised.
https://delcath.org/

.

Absolutely. I've never been a fan of Facebook for a variety of reasons which seems to just now being realized by the majority of users.
This just out:
https://finance.yahoo.com/news/morning-brief-facebook-begin-notifying-users-data-101852133.html
Top news and what to watch in the markets on Monday, April 9, 2018.

Too little, Too late.
News every hour.
https://bringmethenews.com/news/facebook-to-begin-telling-users-if-they-were-affected-by-the-cambridge-analytica-data-leak

Indeed. Shot his age.
I'd been reading, googling and researching some while he played and then finished watching the masters.
Dr's appts all this week and hopefully I'll get some more info regarding the Chemosat trial enrollment while at the facilities.
.
.

I was just surprised you didn't know it :)

You've only been a shareholder since October? Many of us have been holding for approx a year and some even more.
Doesn't matter how long you've held; neither is it of greater or lesser importance.
It may, however, explain why you're not privy to some of the older evidence and concerns.
.
.

Thank you. I'm aware of the proper contact info and have received some additional assistance from our hepatologist as well as our area cancer center but,
still no response.
They, too, are skeptical.
When/if a response of any kind is received, I'll share it.

.

You didn't know that?

Yes. Concerning.

Yes, should have the tires kicked. And certainly debatable for commercial usage, but "hopeful".
This is one reason I'm concerned about why enrollment is low and why there have been no responses to our requests for information on how and where to enroll.

.

It wasn't even necessary to fact-check it. It was an observation written by someone regarding orphan drug designations.
I simply made it clear that the article was written in 2014 and changes were made to designations in 2017.
Much ado about nothing because you'd rather fight than discuss.
.
.

If you've been involved with this company long enough and have read all the filings over at least the last year, then you know the information and the concerns addressed by the website are accurate.
If there's a factual error or even a spell-check failure, you're free to point it out for correction.
You were quite interested in the website until you had a falling-out with a user.
Personality conflicts and hissy-fits don't change facts.
.
.

Can you please point out the error in cited statement?
I was, of course, stating that the observations in the 2014 article may or may not be consistent/pertinent with the changes that have occurred in orphan drug designations since June 2017.
From what I can glean, it is still pertinent and consistent with current usage of orphan drug designation, but was offering that as fact check.
Your point?

True. Broad scope efficacy for all intended usages is still unknown. And it is unknown how long or soon it will be before something better makes it obsolete.
Delcath could've PR'd the wonderful news of the interviews with successfully treated patients last year, but they didn't. They waited till long after the fact to whisper it to US.
We knew about it, but they refused to PR it because it would've helped the pps.
Meanwhile, US enrollment is stagnate and it's not quite clear why.
If we ever receive a reply from those who are in charge of enrollment, one of us will post it.
Regarding Right-To-Try:
Call your Senators.
It never should have taken this long to pass.
.
.
.

Oops, forgot the link. How to copy/paste from a copyrighted website. Hope that helps:)

https://www.shoutmeloud.com/copy-from-right-click-disabled-websites.html

How to copy/paste. Perhaps this will help :)

Yes, that is indeed a strong argument against buyout.
Who'd want it?
We don't really know the true efficacy of this drug and there are others being developed and managed by better companies.

.

SEC is aware. Submitted to SEC before released to public :)

That has never been a secret, so I don't know what the fascination is. Lol. Seems like a lot of desperation here.
Your little alternate group has several iHub users as well and many of them have different monikers for different forums.
And your point would be?

Would love to see that. I hope they crash...hard and fast.

Regardless of the spin anyone tries to put upon it, Zuck will not make a good showing.
https://www.forbes.com/sites/waynecrews/2018/04/08/mark-zuckerberg-testimony-will-washington-cast-the-first-stone-at-facebook/

Orphan Drug Designation: Common misconceptions.

Even when FDA approval is still in the distant future, there's another reason for these early filings. Orphan designations are newsworthy and small companies often use the designation to put themselves on the map and to "gain the interest of the investment community."

Taken from this 2014 article; may or may not still be consistent with updates made in 2017, but interesting.
http://pharmaceuticalcommerce.com/opinion/common-misconceptions-about-the-orphan-drug-designation/

PhD doesn't ensure character and capability. Heather Bresche had her degree revoked.
Just because one speaks negatively of a woman doesn't make them a misogynist.

Then by all means, feel free to disregard the website, the information contained within which is spot-on accurate from what I can glean...
and stop throwing things out to see if they stick, because you cannot discredit the truth and you're wasting your time.
However, if you desire to continue wasting your time, that's your prerogative.

.

Your obsession with the most minutial details regarding the site is funny.
Your disdain for the accuracy of the content contained could be desperation, not sure.
Oh, I forgot to answer a couple of your many insincere questions....

6. No, I am not shorting delcath; however, if I had access to a legal way to short it, I probably would. To date, I've never shorted a stock, altho I have purchased "puts" on some. I've just began experimenting with puts and calls and it's fun.
7. Yes, I / we are delcath long investors. The shares I currently own aren't as numerous as others in our circle, but the size of one's position is relative to their disposable funds. My personal stake is large to me.

I don't like to guess either but based on past experience, if I were to guess, I'd guess that they will get their way by whatever means possible.
I hope my guess is wrong.

.

Interesting!
Intel is developing a discrete gpu arctic sound dedicated to....

https://hothardware.com/news/intel-developing-discrete-gpu-arctic-sound-dedicated-gaming-variant

1. The website was established several months ago and was, best to my recollection, used for different purpose(s) regarding delcath at that particular time. Evidence was gathered among other things. Evidently, you weren't privy. Sorry you were left out since you seem so fascinated by it.
2. The country in which it's registered makes no difference in the great scheme of things, nor in the accuracy of the information contained.
3. I did not set-up the website, but it does not matter to me whether you think I did or not.
Thank you for attributing the credit to me.
4. DCTH is aware of the website

5. The citation regarding approx 90% is easily researched and often in PDF form.
I'll try to help you locate it Altho I'm sure you're capable.

Facebook must Shape-up or Break-up.
http://www.foxnews.com/tech/2018/04/08/facebook-must-shape-up-or-it-will-be-broken-up-senator-warns.html

Re: 10-K

And we know that everything reported in every 10-K is completely accurate, correct?
Research suggests otherwise.

It's the responsibility of each shareholder to read the purposely complicated document and check for inconsistencies that can be found, and to take for granted that carefully disguised ones don't exist.
It's estimated that approx 90% of shareholders never read the 10-K, and the ones who do often don't understand it.
It's our responsibility to pick it apart and we are.

.

Your reservations about "me" are of zero importance.

DCTH is aware of every step we've taken.

When we call, write & email through proper channels requesting info on how to enroll and we receive no response in months, that's rather suspicious.
.
.

Orphan drug rules updated June 2017

https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/ucm588744.htm

It does come up in the search.
Don't know what it indicates this far out.
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm

Enrollment: We're currently doing some research to verify whether they've actually stifled enrollment on their own.
It's a possibility.
.

Operative words = "her mission"

And "her mission" is to preserve "her paycheck".
I see no evidence that
"her mission" ever indicated nor included a plan to properly run this company.

.

SNS, Correction: Not 50 but 100% chance that delcath runs out of money (most likely, judging from past history), regardless of any split or funding scenario unless this management team is gone.
The company-swamp needs to be drained from the top down.

Buy Intel, dump micron.
https://www.barrons.com/articles/buy-intel-dump-micron-advises-ubs-1522963364